Tamoxifen

For research use only. Not for use in humans.

製品コードS1238 別名:ICI 46474

Tamoxifen化学構造

分子量(MW):371.51

Tamoxifen is an antagonist of the estrogen receptor in breast tissue.

サイズ 価格(税別) 在庫  
JPY 26400 あり
JPY 51300 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

生物活性

製品説明 Tamoxifen is an antagonist of the estrogen receptor in breast tissue.
ターゲット
estrogen receptor [1]
体外試験

TAM treatment inhibits significantly MCF7 cell proliferation. Low doses of TAM are able to induce structural chromosomal aberrations (deletions, isochromosomes, translocations, and dicentric chromosomes) in both ER+ and ER- breast cancer cells. This genotoxic effect is higher in those cell lines with HER2 gene amplification[2]. Whereas TAM at lower concentrations (0.1-1 μM) induces a cell-cycle arrest, pharmacological concentrations (above 5 μM) of TAM have been found to induce apoptosis of breast cancer cells. 5 μM TAM rapidly induced sustained activation of ERK1/2 in ER-positive breast cancer cell lines (MCF-7 and T47D)[3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 cells Mk\ZSpVv[3Srb36gZZN{[Xl? Moe2SYZn\WO2aY\lJINwdmOnboTyZZRqd25iYXfhbY5{fCCPQ1[tO{BjemWjc4SgeJVud3JiY3XscJMhfXOrbnegUWNHNTdiYYPzZZktKEWFNUC9NE4xOSEQvF2= MUKxNlgzPTl|NR?=
MCF7 cells NGXyWppEgXSxdH;4bYNqfHliYYPzZZk> M1LaflQ5KGh? Mlq4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFI4KM7:TR?= NFroTYQzOjR5MkC0OS=>
Ishikawa cells MoTiSpVv[3Srb36gZZN{[Xl? M4nldmNwdmOnboTyZZRqd25ib3[gZ49ueG:3bnSgdoVyfWm{ZXSgeI8hcW6mdXPlJFUxKCVib3[geIhmKG2jeHnteY0he3SrbYXsZZRqd25ib3[gZYxs[WyrbnWgdIhwe3CqYYThd4Uh[WO2aY\peJkhcW5iSYPobYtif2FiY3XscJMtKEWFNUC9NE4xOzNizszN M3ywXFgzODF3OEe=
HEK293T cells MlXxSpVv[3Srb36gZZN{[Xl? M1vzO2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiR3HsOEBFSkRvZoXz[YQhcHWvYX6gSXJidHCqYTDMRmQh\XiycnXzd4VlKGmwIFjFT|I6O1RiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBme3S{YXTpc4wucW6mdXPl[EB1emGwc3PybZB1cW:wYXygZYN1cX[jdHnvckBi\nSncjCyNEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwQVAvODN7IN88US=> NXn3OndvOjN5OE[0OVI>
MDA-MB-435 cells M1HjWWZ2dmO2aX;uJIF{e2G7 M2DxPWlvcGmkaYTpc44hd2ZiTVTBMW1DNTR|NTDidoVie3RiY3HuZ4VzKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF0xNjB3IN88US=> MlOyNVQ6PzF6OUm=
MDA-MB-231 cells NU\IenVNTnWwY4Tpc44h[XO|YYm= NEH6d5ZKdmirYnn0bY9vKG:oIHXzeJJw\2WwIILlZ4VxfG:{IH7l[4F1cX[nIF3ERU1OSi1{M{GgZpJm[XO2IHPhcoNmeiClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OC5yODFOwG0> MUGxOFk4OTh7OR?=
T47D cells NFz4R4ZHfW6ldHnvckBie3OjeR?= MUfBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCWNEfEJINmdGy|IHX4dJJme3Orbneg[ZN1em:pZX6gdoVk\XC2b4KgZZN{\XO|ZXSgZZMh\XO2cn;n[Y4u\GWyZX7k[Y51KHS{YX7zZ5JqeHSrb36gZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxRTBwMTFOwG0> M13K[FE6OTNzMkS4
Ishikawa cells NV2yb|ZrTnWwY4Tpc44h[XO|YYm= Ml;OO|IhcA>? M4n2TGFvfGmnc4Tyc4dmdmmlIHHjeIl3cXS7IHnuJIh2dWGwIFnzbIls[XejIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh\XO2cn;n[Y4ucW6mdXPl[EBidGujbHnu[UBxcG:|cHjheIF{\SCjY4Tpeol1gSCjZoTldkA4OiCqcoOsJGlEPTB;MD6xO{DPxE1? MYSxPFg{PTF5Nh?=
MCF-7-2a cells MkjpSpVv[3Srb36gZZN{[Xl? MYjBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDNR2YuPy1{YTDj[YxteyCjczDjc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIILl[JVk\SCnc4TyZYRqd2xiZX\m[YN1KGK7IEWwKUwhUUN3ME2wMlUh|ryP MmLYNVI1OzFyNkO=
EL4 cell NYS4NmgxWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2TaNWlvcGmkaYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIHnueI8hTUx2IHPlcIwheHKxbHnm[ZJifGmxbjygbYM2OD1yLkWzOUDPxE1? NWHkcYpFOTV5M{[zNC=>
HeLa cells NEX0WmxHfW6ldHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKDF5LXLleIEu\XO2cnHkbY9tKG2nZHnheIVlKGy3Y3nm[ZJie2VidILhcpNkemmydHnvckBqdiCKZVzhJINmdGy|IHX4dJJme3OrbnegbJVu[W5iZYP0do9o\W5icnXj[ZB1d3JiYXzwbIE8KEWURTDhd5NigSxiSVO1NF0xNjZ{MjFOwG0> MnrSNVU3PTh6NUG=
MDA-MB-231 cells M3K5ZnBzd2yrZnXyZZRqd25iYYPzZZk> NWLHUHJ3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlY3KM7:TR?= M1LUVVIxPDVzM{iw
T47D cells NV;qVWR[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2f1dVczKGh? MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDld5Rzd2enbj3k[ZBmdmSnboSgWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVA:OSEQvF2= NVjSW2hxOTlzM{GyOFg>
yeast AH109 cells NWPzSXFQTnWwY4Tpc44h[XO|YYm= NHnwV4YzPCCq MVrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYnX0ZUBz\WOncITvdkBNSkRiZYjwdoV{e2WmIHnuJJlm[XO2IFHINVA6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gbY51\XKjY4Tpc44hf2m2aDDTVmMyKGGodHXyJFI1KGi{czDifUBidHCqYT3nZYxi[3Sxc3nkZZNmKGG|c3H5MEBKSzVyPUGuOlYh|ryP NWm3N4dqOjJ4NEeyNVc>
GBM2 cells NXzNXGh{WHKxbHnm[ZJifGmxbjDhd5NigQ>? NUjwPYpJPzJiaB?= MlnaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2yJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9N{42KM7:TR?= NF7N[GYzPjN3NUWzNi=>
NCI-H460 cells NGPG[3pHfW6ldHnvckBie3OjeR?= MoLTNlQhcA>? NGi1dG1CdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF01NjR6IN88US=> NFH3OGMyQTd|M{C4OS=>
GBM3 cells NEKxNpNRem:uaX\ldoF1cW:wIHHzd4F6 M2fKXFczKGh? M2fpWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVQvPyEQvF2= NITNbHUzPjN3NUWzNi=>
DLD1 cells NUPBTplGS3m2b4TvfIlkcXS7IHHzd4F6 NV3ZRZppQTZiaB?= M4jBcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRNTDFiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME20Mlc5KM7:TR?= MVuyNlc1QTN7Mh?=
ScN2a-cl3 cells NITCcJREgXSxdH;4bYNqfHliYYPzZZk> M1fZeFUh\GG7cx?= MljPR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3Wg[Il3cWSrbnegV4NPOmFvY3yzJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSClYXzj[YlvNUGPIIP0ZYlvcW6pLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NF01Njh7IN88US=> M4Xx[FI1OTh|NUi5
K562 cells NXjMfoJsWHKxbHnm[ZJifGmxbjDhd5NigQ>? NYDMbIx4PzJiaB?= Mn\xRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDd{IHjyd{whUUN3ME21MlIh|ryP M2DHZlI2PDJyMUe1
MDA-MB-435S cells NG\RWFREgXSxdH;4bYNqfHliYYPzZZk> NFjoU3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2WyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:PS53IN88US=> MY[yOlA4QTB7MB?=
DU145 cells MYrQdo9tcW[ncnH0bY9vKGG|c3H5 NF7LO2s1QCCq NI\oXolCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NT61JO69VQ>? M{W4U|I{Ojh5MEW3
HepG2 cells NHnCU3NRem:uaX\ldoF1cW:wIHHzd4F6 MnfkOFghcA>? M165fmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD14LkOg{txO M{S2clI{Ojh5MEW3
SKOV3 cells MV\GeY5kfGmxbjDhd5NigQ>? M4HTbVI1KGh? Ml\KRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLU3Y{KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;Nj60JO69VQ>? MXqxPVc{OzB6NR?=
PC3 cells NWfpd4RjWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUCyOEBp NEnXVFNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdizszN MXeyOFg5ODJ|MB?=
NIH/3T3 cells NYDXTlRTS3m2b4TvfIlkcXS7IHHzd4F6 M1\0PVk3KGh? M3vk[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9|VEOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF04NjJ4IN88US=> NYHid5hOOjJ5NEmzPVI>
GBM1 cells NIW3fopRem:uaX\ldoF1cW:wIHHzd4F6 NFGzNZA4OiCq MljORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2xJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9O{42KM7:TR?= MkPGNlY{PTV3M{K=
518A2 cells NFHaWHVEgXSxdH;4bYNqfHliYYPzZZk> NGDtXJo6PiCq NIG5[otEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVcvPjJizszN NF;XeZkzOjd2OUO5Ni=>
A2780 cells NFvCeHBEgXSxdH;4bYNqfHliYYPzZZk> MYS5OkBp NUKzfGpSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF04Njd5IN88US=> MVOyNlc1QTN7Mh?=
A549 cells NX7lZ|djS3m2b4TvfIlkcXS7IHHzd4F6 NXKzPWlwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCkeTDNWHQh[XO|YYmsJGlEPTB;OD60JO69VQ>? NUn3RZQxOjZyN{mwPVA>
Lipo cells NYKz[XBNS3m2b4TvfIlkcXS7IHHzd4F6 M1fMcVk3KGh? M2r3[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxqeG9iY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME24MlY1KM7:TR?= NFHvbW4zOjd2OUO5Ni=>
A253 cells NHrVSFNEgXSxdH;4bYNqfHliYYPzZZk> NFfTdlI6PiCq Mn;LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI2OyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUiuPVIh|ryP NHXJUFgzOjd2OUO5Ni=>
HT-29 cells MlvKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIWE0zQSClZXzsd{whUUN3ME25MlUh|ryP M3f0c|I{PDB|MEi0
LNCAP cells NWfZNmhYWHKxbHnm[ZJifGmxbjDhd5NigQ>? MoXwOFghcA>? NYjvZXhDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{BmgHC{ZYPzbY5oKGGwZILv[4VvKHKnY3XweI9zKGmwY4XiZZRm\CC5aYToJFAvPiCwTTDv[kBme3S{YXTpc4wh[W6mIECuO{BvVSCxZjD0[ZN1d3O2ZYLvcoUh[W[2ZYKgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OTBizszN M2LyWlIyPTF|Mke1
M21 cells M2DPPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjNToVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOOjFiY3XscJMtKEmFNUC9NVEh|ryP M1vaO|I{PDB|MEi0
850C cells Ml\5R5l1d3SxeHnjbZR6KGG|c3H5 MmjOPVYhcA>? NEfRPZdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTCFIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NVEvODlizszN MX[yNlc1QTN7Mh?=
HL60 cells NVjLN2F4S3m2b4TvfIlkcXS7IHHzd4F6 NFT0boQ4OiCq NYnYUHlvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhX1OWMTDhd5NigSCrbjDwdoV{\W6lZTDv[kAzOCViRlLTMEBKSzVyPUG0MlMh|ryP MWWyNlkxOTh7NR?=
MSTO-211H cells MlvzVJJwdGmoZYLheIlwdiCjc4PhfS=> MkHIO|IhcA>? MnT2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPU2TPMVIyOUhiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJRzgXCjbjDicJVmKGG|c3H5MEBKSzVyPUKzMlMh|ryP MmrQNlM4OzV6Mkm=
HepG2 cells NIL6eJpEgXSxdH;4bYNqfHliYYPzZZk> NV\3NWlSOjRiaB?= MkW0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JGNmdGyWaYTldk1DdHWnQ3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkOuOO69VQ>? M3\4UVIxPTR3M{O0
KIF5 cells NF:1SGZEgXSxdH;4bYNqfHliYYPzZZk> MV:yOEBp NGTSV3VVd3irY3n0fUBi\2GrboP0JIh2dWGwIFvJSlUh[2WubIOgbY5kfWKjdHXkJIZweiB{NDDodpMh[nliQ3XscHRqfGW{IFLseYUh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjNwN{Wg{txO NE\POJIzOjd5NUS3OC=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-AKT / AKT; 

PubMed: 30759864     


MCF-7 cells were treated with 2 μM tamoxifen and harvested at the indicated time point to analyze the expressions of p-AKT and AKT by western blot.

ER-α66 / ER-α36 / HER2 / EGFR; 

PubMed: 25203051     


Western blot analysis of the expression levels of ER-α66, ER-α36, HER2 and EGFR in ER-positive breast cancer MCF7 (A), T47D (B) and H3396 (C) cells treated with 1 µM of tamoxifen (TAM) for indicated time period.

p-AMPK / AMPK / p-ACC / ACC / p-P70S6K / p-S6 / p-4EBP1; 

PubMed: 27020861     


B. Immunoblot of AMPK pathway activation following treatment with 30μM tamoxifen in MCF7 and C. in MDA-MB-231 cells. 

CD36 / p-ERK / ERK ; 

PubMed: 30573731     


MCF-7 cells MCF-7 cells were treated with tamoxifen (Tam) at the indicated concentrations for 16 h, or with 5 μM Tam for the indicated times. Expression of CD36, p-ERK1/2 and ERK1/2 was determined by western blot.

30759864 25203051 27020861 30573731
Immunofluorescence
CD36; 

PubMed: 30573731     


MCF-7 cells were treated with tamoxifen (Tam) at the indicated concentrations for 16 h. Expression of CD36 was determined by immunofluorescent staining. 

30573731
体内試験 Tamoxifen (TAM) is widely used for both treatment and prevention of breast cancer. However, it is also carcinogenic in human uterus and rat liver[2]. Tm-inducible Cre-loxP systems are being used in broad areas of research and are providing important biologic insights in tissue development, maintenance, and function. Tamoxifen-induced nuclear localization of Cre recombinase is time- and dose-dependent. Higher doses of tamoxifen induce recombination weeks following administration and Lower doses of tamoxifen induce recombination up to one week following administration. Duration of tamoxifen-induced gene recombination is also dose-dependent. Administration of high Tm doses leads to extended CreER nuclear localization. Tm treatment induces side effects that may have physiologic consequences in Tm-inducible models[4].

お薦めの試験操作(参考用のみ)

細胞試験:

[2]

- 合併
  • 細胞株: MCF7 and T47D
  • 濃度: 10-6 mol/L
  • 反応時間: 24, 48, and 96 h
  • 実験の流れ:

    48 h before the addition of E2 and TAM, cells were washed with 5 mL phosphate-buffered saline (PBS) and then switched to phenol red-free RPMI-1640 containing 10% charcoal-stripped FBS. E2 and TAM were dissolved in absolute ethanol and diluted in the media at 10<sup>-8</sup> mol/L and 10<sup>-6</sup> mol/L, respectively, and then added to the culture medium at 24, 48, and 96 h.


    (参考用のみ)
動物試験:

[4]

- 合併
  • 動物モデル: Pdx1PB-CreERTm mice
  • 投薬量: --
  • 投与方法: s.c.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 74 mg/mL (199.18 mM)
Ethanol 74 mg/mL (199.18 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
1mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 371.51
化学式

C26H29NO

CAS No. 10540-29-1
保管
in solvent
別名 ICI 46474
Smiles CC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(OCCN(C)C)C=C3.OC(=O)CC(O)(CC(O)=O)C(O)=O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(余分な消耗を考慮し動物一匹分の量を用意することをお勧めします。)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロットごとに組成が異なるため、セレックから完全に溶解できる組成をお求めください。)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04174352 Suspended Drug: Tamoxifen|Diagnostic Test: FES PET/CT ERα+ Breast Cancer|ESR1 Gene Mutation University of Wisconsin Madison June 2020 Early Phase 1
NCT04200066 Not yet recruiting Drug: Temozolomide Tamoxifen Maprotiline Glioblastoma|Brain Tumor University of Rochester February 1 2020 Phase 1
NCT04312347 Recruiting Drug: Tamoxifen dose adjustment ER+ Breast Cancer Nalagenetics Pte Ltd September 6 2019 Not Applicable
NCT03582865 Not yet recruiting Drug: Tamoxifen 20 mg Breast Cancer Assiut University September 1 2019 --
NCT02801786 Not yet recruiting Drug: Placebo|Drug: Lidocaine|Drug: Tamoxifen Pain|Discomfort Universidade Federal de Goias November 2018 Phase 2|Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Could you tell me if you have a protocol for the use of tamoxifen (S1238) in vivo in mouse? Is there an administration way that is better than another?

  • 回答:

    Tamoxifen (S1238) can be dissolved in 10% ethanol/10% Tween 80/ddH2O at 5 mg/ml clearly. But precipitation will form if the formulation was left at RT for an hour or longer. So we'd suggest that you use it quickly after formulation. Tamoxifen is often administrated via i.p injection.

Tags: Tamoxifenを買う | Tamoxifen ic50 | Tamoxifen供給者 | Tamoxifenを購入する | Tamoxifen費用 | Tamoxifen生産者 | オーダーTamoxifen | Tamoxifen化学構造 | Tamoxifen分子量 | Tamoxifen代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID